ID   RED-3
AC   CVCL_8907
DR   BioSample; SAMN03151777
DR   cancercelllines; CVCL_8907
DR   Wikidata; Q54949691
RX   CelloPub=CLPUB00690;
RX   CelloPub=CLPUB00691;
RX   PubMed=2659902;
RX   PubMed=12592342;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HL-60 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 24 year old male patient suffering from acute lymphoblastic leukemia in second relapse.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00260.
CC   Population: Caucasian.
CC   Doubling time: 26 hours (CelloPub=CLPUB00690; CelloPub=CLPUB00691).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=2659902).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 27
//
RX   CelloPub=CLPUB00690;
RA   Knight R.D., Khan E.C., Mallet M.R., Wright D.G.;
RT   "Establishment of a new myeloid cell line from a patient with TdT(+)
RT   acute leukemia.";
RL   Blood 66 Suppl. 1:224a-224a(1985).
//
RX   CelloPub=CLPUB00691;
RA   Mallet M.R., Knight R.D., Khan E.C., Wright D.G.;
RT   "Characterization of RED-3: a biphenotypic myeloid leukemia cell line.";
RL   Fed. Proc. 45:958-958(1986).
//
RX   PubMed=2659902;
RA   Mallet M.K., Mane S.M., Meltzer S.J., Needleman S.W.;
RT   "c-myc amplification coexistent with activating N-ras point mutation
RT   in the biphenotypic leukemic cell line RED-3.";
RL   Leukemia 3:511-515(1989).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//